Patents
Neuroprotective peptides
Patent Number: 7,259,146This patent covers specific peptides derived from erythropoietin, as well as from other molecules, that have ability to increase neurite outgrowth in cell culture. Specifically, the claims appear to be restricted only to a method of increasing neurite outgrowth in cell culture. The neuroprotective roles of erythropoietin have been known for many years and have been assessed and are being...
Inventors: Smith-Swintosky; Virginia (Hatfield, PA), Renzi; Michael (Harleysville, PA), Plata-Salaman; Carlos (Ambler, PA), Jolliffe; Linda (Belle Mead, PA), Farrell; Francis (Doylestown, PA), Johnson; Dana (Upper Black Eddy, PA)
Assignee: Ortho-McNeil Pharmaceutical, Inc. (Raritan, NJ)
Date of First Priority Issue: Friday May 26th, 2000
Isolation, selection and propagation of animal transgenic stem cells
Patent Number: 7,256,041This patent covers the use of genetic markers to "fish out" stem cells from a heterogeneous population. Essentially, the patent teaches: 1. Culturing mammalian cells with a construct in which a selectable marker is turned on by a promoter which is only active in stem cells. 2. Isolating stem cells based on the selectable marker. This is a very broad patent !!
Inventors: Smith; Austin Gerard (Edinburgh, GB), Mountford; Peter Scott (Melbourne, AU)
Assignee: The University of Edinburgh (Edinburgh, GB)
Date of First Priority Issue: Wednesday April 21st, 1993
Post-partum mammalian placenta, its use and placental stem cells therefrom
Patent Number: 7,255,879This patent covers a mesenchymal-like stem cell obtained by first flushing a placenta so that cord blood is substantially cleared, and subsequently perfusing the placenta to collect cells that are CD34 negative and have stem cell properties. The cell type covered appears to be: positive for one or more of the following markers: SH2, SH3, SH4, CD10, CD29, CD44, CD54, CD90, and OCT-4, AND...
Inventors: Hariri; Robert J. (Florham Park, NJ)
Assignee: Anthrogenesis Corporation (Cedar Knolls, NJ)
Date of First Priority Issue: Wednesday December 6th, 2000
Methods for cloning non-human mammals using reprogrammed donor chromatin or donor cells
Patent Number: 7,253,334This patent covers the use of epigenetically reprogramming a donor nucleus prior to cloning. Essentially Collas uses methods he previously described as able to induce dedifferentiation of adult cells. In previous papers, Collas demonstrated that tranfering cytoplasm from a T cell into a fibroblast (through temporarily permeabilizing the fibroblast), will allow the fibroblast to express T cell...
Inventors: Collas; Philippe (Oslo, NO), Robl; James M. (Belchertown, MA), Sullivan; Eddie (Manhattan, KS), Kasinathan; Poothappillai (Brandon, SD)
Assignee: Aurox, LLC (Westport, CT)
Date of First Priority Issue: Friday December 21st, 2001
Oral compositions for white blood cell activation and proliferation
Patent Number: 7,256,026This patent covers an "activated yeast" preparation that is useful for stimulating production of white blood cells. The activation of the yeast cells is described using various electromagnetic fields. Interestingly, the yeast may be orally administered for augmentation of white blood cell number and activity. This is particularly useful for the treatment of immune suppressed patients either...
Inventors: Cheung; Ling Yuk (Hong Kong, HK)
Assignee: Ultra Biotech Limited (Douglas, IM)
Date of First Priority Issue: Friday June 28th, 2002
Process for making hepatocytes from pluripotent stem cells
Patent Number: 7,256,042This patent covers methods of differentiating embryonic stem cells into hepatocytes. Hepatocytes are very attractive since they can be used as a single cell therapy for restoring cirrhotic livers. The patent covers the use of the differentiation agents:sodium butyrate, n-butyric acid, trichosratin A, propionic acid, isobutyric acid, and isovaleric acid for generating hepatocytes. The patent...
Inventors: Rambhatla; Lakshmi (Redwood City, CA), Carpenter; Melissa K. (Castro Valley, CA)
Assignee: Geron Corporation (Menlo Park, CA)
Date of First Priority Issue: Thursday April 27th, 2000
2 Comments
2 Comments
Method of generating neurons from stem cells and medium for culturing stem cells
Patent Number: 7,252,995This patent covers the use of medium obtained from the supernatant of cultured hippocampal neurons for use in the induction of neural differentiation of stem cells. The stem cells that can be differentiated into neurons by culture in the media include: - Embryonic stem cells - Embryonic germ cells - Embryonic carcinoma - Bone marrow stromal cells - Bone marrow hematopoietic cells...
Inventors: Fu; Yu-Show (Taipei, TW), Cheng; Henrich (Taipei, TW)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Friday December 13th, 2002
1 Comment
1 Comment
Quantitative RT-PCR to AC133 to diagnose cancer and monitor angiogenic activity in a cell sample
Patent Number: 7,252,976Based on the title, one would think that this patent covers global use of PCR amplifying for CD133 transcripts in order to detect angiogenic propensity in a host. If this were the case, then the patent indeed would be very strong. The patent, however, is restricted to covering the diagnosis of colorectal cancer using PCR amplification of CD133 transcripts in peripheral blood. This...
Inventors: Lin; Edward H. (Houston, TX), Wu; Xifeng (Pearland, TX), Xie; Keping (Pearland, TX)
Assignee: Board of Regents the University of Texas System (Austin, TX)
Date of First Priority Issue: Wednesday August 28th, 2002
Screening small molecule drugs using neural cells differentiated from human embryonic stem cells
Patent Number: 7,250,294When people wonder why Geron's valuation is so high (half a billion) even though they are far from the clinic...well the answer is strong IP such as the current patent. This patent blocks anyone from differentiating neurons from embryonic stem cells and using them to screen compounds for: 1. toxicity 2. viability in culture 3. induction of alterations in neurotransmitter synthesis...
Inventors: Carpenter; Melissa K. (Castro Valley, CA), Denham; Jerrod J. (San Francisco, CA), Inokuma; Margaret S. (San Jose, CA), Thies; R. Scott (Pleasanton, CA)
Assignee: Geron Corporation (Menlo Park, CA)
Date of First Priority Issue: Wednesday May 17th, 2000
Methods for identifying compounds which modulate hematopoiesis
Patent Number: 7,250,262This patent covers the monitoring of numerous genes as a marker of hematopoietic stem cells proliferation, differentiation, and/or induction into apoptosis. This patent is useful for screening of compounds for potential hematopoietic modulatory activity, as well as in vivo assessment of drugs. Particularly, in clinical trials it is better if some of these "biomarkers" can be prognostic of upcoming...
Inventors: Carroll; Joseph M. (Cambridge, MA), Healy; Aileen (Medford, MA), Weich; Nadine S. (Brookline, MA), Kelly; Louise M. (Brookline, MA)
Assignee: Bayerhealth Care AG (Leverkusen, DE)
Date of First Priority Issue: Monday February 4th, 2002